The three budding yeast CLN genes appear to be functionally redundant for cell cycle Start: any single CLN gene is sufficient to promote Start, while the cln1 cln2 cln3 triple mutant is Start defective and inviable. Both quantitative and apparently qualitative differences between CLN genes have been reported, but available data do not in general allow distinction between qualitative functional differences as opposed to simply quantitative differences in expression or function. To determine if there are intrinsic qualitative differences between Cln proteins, we compared CLN2, CLN3, and crippled (but still partially active) CLN2 genes in a range of assays that differentiate genetically between CLN2 and CLN3. The results suggest that different potencies of Cln2, Cln3, and Cln2 mutants in functional assays cannot be accounted for by a simple quantitative model for their action, since Cln3 is at least as active as Cln2 and much more active than the Cln2 mutants in driving Swi4/Swi6 cell cycle box (SCB)-regulated transcription and cell cycle initiation in cln1 cln2 cln3 bck2 strains, but Cln3 has little or no activity in other assays in which Cln2 and the Cln2 mutants function. Differences in Cln protein abundance are unlikely to account for these results. Cln3-associated kinase is therefore likely to have an intrinsic in vivo substrate specificity distinct from that of Cln2-associated kinase, despite their functional redundancy. Consistent with the idea that Cln3 may be the primary transcriptional activator of CLN1, CLN2, and other genes, the activation of CLN2 transcription was found to be sensitive to the gene dosage of CLN3 but not to the gene dosage of CLN2.
The Start transition in the Saccharomyces cerevisiae cell cycle requires the activity of one of three cyclin homologs encoded by the CLN1, CLN2, and CLN3 gene family, complexed with the cyclin-dependent kinase encoded by the CDC28 gene. Although the CLN genes are functionally redundant for cell cycle Start (39) , the CLN3 gene differs sharply from the CLN1-CLN2 gene pair in structure and regulation (see reference 7 for a review). Searches for mutations resulting in lethality in strains deficient in CLN1 and CLN2 have yielded mutations in a wide range of genes, with widely varying lethal phenotypes. The general conclusion from this result has been that Cln1 and Cln2 are potent at execution of various cell biological processes associated with Start (e.g., cell polarization [4, 12] and septin ring formation [4, 18] ), while Cln3 is relatively weak at activating these processes. Mutations in one gene (BCK2) are lethal in the absence of CLN3 but not in the absence of CLN1 and CLN2. The latter defect is significantly but not completely rescued by placing CLN2 under the control of heterologous promoters (14, 20) , as Bck2 is required for efficient transcriptional activation of CLN1 and CLN2 in the absence of CLN3. This result is consistent with other data which suggest that Cln3 is the main or only physiological activator of CLN1 and CLN2 transcription (15, 43, 44) . These results have led to a picture in which Cln3 predominantly functions to activate CLN1 and CLN2 transcription, while Cln1 and Cln2 carry out various Start-specific processes; Cln3 may be able to carry out these processes only with the aid of various accessory pathways. Other cyclins (the CLB5-CLB6 pair of B-type cyclins and the PCL1-PCL2 pair of cyclins that activate the Pho85 kinase) are also essential in the absence of CLN1 and CLN2 (see reference 7 for a review), suggesting that they may, like CLN3, have accessory or backup roles for the functions normally performed by CLN1 and CLN2.
The results summarized above can be interpreted in two different ways. (i) Cln3-Cdc28 could simply be a weak, lowabundance kinase with no intrinsic difference in specificity compared to other cyclin-Cdc28 complexes; its biological role as an activator of CLN1,2, CLB5,6, and PCL1,2 transcription may come about solely because the CLN3 promoter allows expression in early G 1 at a time when other more potent cyclins are not expressed. (ii) Cln3-Cdc28 could have intrinsic differences in specificity of action compared to Cln1,2-Cdc28 or Clb5,6-Cdc28, resulting in potent activity for a subset of Startspecific processes (probably including transcriptional activation) but an inability to execute other processes. Because most of the experiments performed previously and summarized above have not controlled for differences in expression or abundance of Cln3 and Cln1 or Cln2, it is difficult to choose between these two explanations. Here we investigate the qualitative differences between Cln2 and Cln3 by normalizing their expression and assaying for function both in vivo and in vitro. We also analyze the effects of alteration of CLN2 and CLN3 gene dosage on timing of bud emergence and CLN2 expression.
MATERIALS AND METHODS
Plasmid constructions. The CLN2 coding sequence with the triple-hemagglutinin (HA) tag (CLN2C [44] ) was obtained from M. Tyers (MT104). The CLN2 coding sequence under control of the CLN3 promoter (CLN2-3P [46] ) was obtained from C. Wittenberg (pHV104). These constructs were recombined in the low-copy-number vector RS314 (42) as follows. The HV104 SalI-SpeI fragment from the CLN3 promoter to the SpeI site in the CLN2 coding sequence was subcloned into SalI-SpeI-digested RS314. The BamHI site at the CLN3 promoter-CLN2 junction was converted to a ClaI site by BamHI digestion, Klenow fragment fill-in, and ligation. The MT104 SpeI-HpaI fragment from the CLN2C coding sequence to the HpaI site in the adjacent LEU2 gene was subcloned into the above plasmid cut with NotI, blunted with Klenow fragment, and cut with SpeI. The resulting plasmid was named pT411 (CLN2C coding sequence under control of the CLN3 promoter, in a low-copy-number TRP1 vector). The CLN3 coding sequence with the triple-HA tag (CLN3C [45] ) was obtained from M. Tyers (BF030CW). BF030CW was used as template to amplify the CLN3C coding sequence in a thermal cycling reaction using Vent polymerase (New England Biolabs) according to the manufacturer's instructions. Vent polymerase is a high-fidelity DNA polymerase with a reported error rate of less than 1 in 10 4 bp; we therefore consider it unlikely that mutations were introduced during amplification. The resulting product was digested with ClaI (introduced upstream of the CLN3 ATG at the same position as the ClaI site in pT411 relative to the CLN2 ATG) and BamHI (cutting in the epitope tag) and subcloned into pT411 digested with BamHI and ClaI, producing pKL001 (identical to pT411 but with CLN3C instead of CLN2C under control of the CLN3 promoter). The insert from pKL001 from SalI to SacII (cutting in polylinker) was transferred to SalISacII-digested RS424 (5), producing a high-copy-number (2m origin) CLN3C plasmid, pKL034. The GAL1 promoter was amplified by thermal cycling using plasmid BM272 (from M. Johnston) as the template. The product was digested with SalI (from pBR322 vector sequence) and ClaI (introduced in oligonucleotide primer) and subcloned into pKL001 digested with SalI and ClaI, to produce pKL002 (GAL1::CLN3C). CLN2C coding sequences were substituted for CLN3C coding sequences in pKL002 by digesting pKL002 and pT411 with ClaI and BamHI and switching insert fragments to produce pKH100 (GAL1::CLN2C). Mutant CLN2 genes containing alanine substitutions for Lys129 or Glu183 were constructed by splice-overlap extension (22) using pT411 as the template and Vent polymerase. Amplified fragments were subcloned into pT411 by ClaIBamHI digestion to produce pKL003 (cln2-K129A-3P) and pKL004 (cln2-E183A-3P) (identical in structure to pT411 except for the alanine substitutions). The mutations were confirmed by DNA sequencing. The double cln2-K129A,E183A-3P mutant (pKL005) was constructed by cutting pKL003 and pKL004 with SpeI and BamHI and recombining appropriate fragments. ClaIBamHI fragments containing these mutant CLN2 genes were transferred into pKL002 to produce GAL1 promoter-driven derivatives.
Yeast strains and genetic procedures. Standard methods were used for all strain constructions and transformations (21) . Mutant alleles used were CLN gene deletions described elsewhere (10), clb5::ARG4 (19), clb6::ADE1 (3), pcl1::URA3 and pcl2::HIS3 (30), swi4::LEU2 (9), swi6::LEU2 (provided by B. Andrews), bck2::ARG4 (20), GAL1::SIC1 (13), and bud2::URA3 (4). All mutant alleles used were null alleles (deletion or disruption alleles). All strains were congenic with BF264-15D (39) ( Table 1) .
Protein extraction, immunoprecipitation, immunoblotting, and protein kinase assays. The procedures were adapted from Cross and Blake (8) and Tyers et al. (44, 45) . Yeast cultures (100 ml at an optical density at 660 nm [OD 660 ] of 1.0) were collected by filtration and resuspended in ice-cold LSHN (10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid [HEPES; pH 7.5], 50 mM NaCl, 10% glycerol). Cells were resuspended in 250 l of TNN extraction buffer (50 mM Tris [pH 7.5], 250 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-40, 10% glycerol) containing 5% aprotinin (Sigma), 0.1 mM phenylmethylsulfonyl fluoride, 10 g of leupeptin per ml, 10 g of pepstatin per ml, 10 mM NaPPi (pH 7.4), and 10 mM NaF. Four hundred microliters of acid-washed glass beads (Sigma) was added, and cells were broken by three cycles of 1 min of vortexing in a Vortex-Genie sleeve at top speed. Breakage was performed at 4ЊC. Between cycles, extracts were microcentrifuged briefly to condense foam, and unbroken cells were resuspended by stirring with a micropipettor tip. Extracts were microcentrifuged, 250 l was removed, and another 250 l of extraction buffer was added to cells and beads. After 1 min of vortexing, the sample was microcentrifuged and the extraction buffers were combined. The extracts were clarified by 2 min of microcentrifugation and incubated with 7 g of monoclonal antibody 12CA5 (from ascites fluid; Babco) for 1 to 2 h on ice. Samples were microcentrifuged for 2 min, and supernatant was added to 30 l of slurry of protein A-agarose (Repligen) washed in extraction buffer. Samples were rotated at 4ЊC for 1 to 2 h. Immunoprecipitates were washed with extraction buffer three times for 1 min each and once for 2 min. Immunoprecipitates were washed once in kinase assay buffer (10 mM HEPES [pH 7.4], 10 mM MgCl 2 , 10% glycerol, 1 mM dithiothreitol) and resuspended in 60 l of kinase assay buffer, and 15 l of the suspension was added to 1 l of histone H1 (2 mg/ml; Boehringer Mannheim)-2 l of 50 M ATP-1 l of water-1 l of [␥-
32 P]ATP (NEN). These kinase reaction mixtures were incubated at 30ЊC for 10 min with shaking every 2 to 3 min. Reactions were stopped by addition of 20 l of 2ϫ sodium dodecyl sulfate (SDS) sample buffer (2) and heating to 95ЊC for 5 min. The remainder of the immunoprecipitate was collected by centrifugation, resuspended in 60 l of 2ϫ SDS sample buffer, heated at 95ЊC for 5 min, and used for immunoblot analysis. SDS-polyacrylamide gel electrophoresis and transfer to Immobilon were done as described previously (8) . Following transfer, radioactivity in histone H1 was quantitated with a PhosphorImager (Applied Biosystems). Blots were blocked in phosphate-buffered saline (PBS) solution containing 0.5% Nonidet P-40, 0.1% Tween 20, 0.5% bovine serum albumin, and 2.3% milk (Carnation). Antibody incubations were in PBS-Tween (0.2%), with 1 to 2% milk included to reduce background. Antibodies used were a polyclonal rabbit anti-HA peptide antibody (Babco) to detect the HA tag and an anti-C-terminal Cdc28 polyclonal rabbit antibody provided by R. Deshaies. Detection was by enhanced chemiluminescence (ECL) using an ECL kit (Amersham). ECL signals were quantitated from autoradiographs by using a DeskScan II scanner (Hewlett-Packard) and ImageQuant software.
Plating efficiency assays. Mutant strains, containing either a GAL1::CLN1 gene essential for viability or the GAL1::SIC1 gene, were transformed with
For each transformed strain, 10-fold serial dilutions were prepared for two independently isolated transformants, and 5 l of each dilution was plated onto both a YEP-galactose (YEPGal) plate and a YEP-dextrose (YEPDex) plate. Plates were incubated at 30 or 38ЊC for 2 to 3 days. The plating efficiencies were determined by counting the colonies at each dilution (where colony density allowed), calculating an average colony count (corrected for dilution) for each transformant, and then calculating the plating efficiency as a fraction of the average colony count on the test plate (YEPDex plate for all strains except YEP Gal for the GAL1::SIC1 strain) to the average colony count on the control plate (YEPGal plate for all strains except YEPDex for the GAL1::SIC1 strain). The plating efficiency assays indicated on the graphs in Fig. 4 represent the averaged values (arithmetic mean) of two independent transformants. The maximum decrease in plating efficiency that can accurately be detected in the assays presented in Fig. 3 and 4 is approximately 1,000-fold. Note that in our strain background, the lethality of cln1 cln2 cln3 pcl1 pcl2 strains transformed with the CLN3 plasmid was variable at 30ЊC, and so the quantitative data presented in Fig. 4 are from incubation at 38ЊC. However, qualitatively the same order of efficiency of rescue was observed for pcl1 pcl2 strains at 30ЊC (data not shown). We also tested a cln1 cln2 erc10-1 strain, since Cla4 (Erc10) is required for septin ring formation and cytokinesis in the absence of Cln1 and Cln2 (4, 11) . We found qualitatively similar results, with the efficiency of rescue CLN2 Ͼ CLN2-E183A Ͼ CLN2-K129A Ͼ CLN2-K129A,E183A ϳ CLN3. High-copy-number CLN3 was no better at rescuing this strain than was low-copy-number CLN3. However, the degree of rescue of plating efficiency obtained with the various CLN genes was quite variable in this strain for unknown reasons, and so we cannot present quantitative data.
Cell volume assay. Cells of the cln1 cln2 cln3 (1254-14D) strain containing the GAL1::CLN1 gene, which is essential for viability, were transformed with plasmid T411 (CLN2-3P), KL004 (cln2 E183A-3P), KL003 (cln2 K129A-3P), or KL001 (CLN3-3P). All plasmids are episomal centromeric (CEN) (low copy number) and carry the TRP1 gene. For each transformant strain, stock cultures of two individual transformants were grown in defined (synthetic complete [SC]) medium containing 3% galactose and lacking tryptophan (SCGal-Trp). Stock cultures were used to inoculate YEPDex, and cultures were grown overnight to an OD 660 of ϳ1.0. Cells from each culture were fixed in 10% formaldehyde and sonicated to disperse clumps. Cell volume analysis was done with a Coulter Channelyzer 256.
Assay of expression from a Swi4/Swi6 cell cycle box (SCB)-lacZ plasmid. Plasmid BD53 (URA3-3ϫ-SCB-lacZ) was obtained from Linda Breeden. This plasmid gave expression of lacZ (measured as described elsewhere [2] ) that was genetically dependent on SW14 and SW16 as expected (data not shown) (see VOL. 16, 1996 FUNCTIONAL SPECIFICITIES OF YEAST G 1 CYCLINS 6795 reference 27 for a review). This plasmid was transformed into cln1 cln2 cln3 leu2::LEU2::GAL1::CLN3 bck2::ARG4 strains (20) , and the resulting strain was secondarily transformed with plasmid KL001 (CLN3-3P), T411 (CLN2-3P), KL004 (cln2 E183A-3P), KL003 (cln2 K129A-3P), or pRS414. Transformant strains were grown overnight in defined medium containing 3% galactose and lacking both tryptophan and uracil (SCGal-Trp-Ura). Strains were shifted from galactose-containing medium to dextrose-containing medium (SCDex-Trp-Ura) and grown for an additional 24 h; this prolonged incubation in dextrose medium (GAL1::CLN3 off) was needed to minimize the background activity observed in the pRS414 transformant strain, presumably arising from inheritance of stable ␤-galactosidase from pregrowth in galactose medium (GAL1::CLN3 on). After 24 h, the cultures were each diluted in SCDex-Trp-Ura and allowed to grow to mid-log phase. ␤-Galactosidase liquid assays were carried out as described previously (2) . Centrifugal elutriation and RNA hybridization analysis. The analyses were carried out as described previously (35) . Strains used were diploid strains varying in CLN2 and CLN3 gene dosage. The tandem integrated 3ϫ CLN3 allele was described previously (34) . This tandem integration of the CLN3 gene at the TRP1 locus results in approximately threefold elevation of CLN3 mRNA and protein production (8a). All diploid strains contained GAL1::CLN3 cassettes, but these were inactive since all culture growth for this experiment was in rich glucose-containing medium (YEPDex).
RESULTS

Construction of reduced-function alleles of CLN2.
To begin sorting out the relative contributions of qualitative and quantitative differences between CLN2 and CLN3, we constructed alleles of CLN2 with reduced function. We relied on the cyclin A-Cdk2 crystal structure and the sequence homology between cyclin A and CLN2. Lys266 and Glu295 of cyclin A hydrogenbond to each other and to the backbone of the critical PSTAIRE helix of Cdk2 (24) . We mutated the corresponding Lys129 and Glu183 of CLN2 to alanines, separately or in combination.
Cln2-, Cln3-, and mutant Cln2-associated Cdc28 and kinase activity. We used the triple-HA-epitope-tagged versions of the CLN2 and CLN3 coding sequence described by Tyers et al. (44, 45) . These coding sequences were placed under the control of the CLN3 or the GAL1 promoter on episomal CEN (low-copy-number) plasmids. We used the GAL1 promoterdriven constructs of CLN2, CLN3, and the CLN2 mutants to examine Cdc28 association and kinase activity, since this gave us more easily quantitated data than did the CLN3 promoterdriven constructs. We found an approximately 20-fold reduction in Cln3-associated kinase activity compared to Cln2-associated kinase activity when kinase activity was standardized to Cln protein ( Fig. 1 and data not shown) . Therefore, the defect in recovery of Cln3-associated kinase activity compared to Cln2-associated kinase activity under these conditions (44) is due to an intrinsic defect in Cln3-associated kinase activity toward histone H1, not solely to low recovery of Cln3 compared to Cln2. Although we reproduced the qualitative result of Cdc28 binding to Cln3 (45), we were unable to obtain a reproducible quantitative comparison between the efficiency of Cln2 and Cln3 binding to Cdc28 for unknown reasons. (We cannot exclude the possibility that the presence of the HA tag, or the constitutive overexpression of the proteins from the GAL1 promoter, perturbs these results relative to the wildtype situation.)
Compared to wild-type Cln2, the Cln2 mutant proteins had significantly decreased associated kinase activity and Cdc28 binding (Fig. 1) . The K129A,E183A double mutant was almost inactive in these assays. These residues are surface residues in FIG. 1. Comparison of associated kinase activity, associated Cdc28 protein, and associated Cdc28-specific kinase activity for HA-tagged Cln proteins expressed from the GAL1 promoter. Wild-type cells (1255-5C) were transformed with plasmid pRS414, KH100 (GAL1::CLN2), KL029 (GAL1::cln2 K129A), KL030 (GAL1::cln2 E183A), KL031 (GAL1::cln2 K129A,E183A), or KL002 (GAL1::CLN3) (lanes 1 to 6 in panel A). All plasmids are episomal CEN (low copy number) and carry the TRP1 gene. Cultures of each transformant strain were grown overnight at 30ЊC in SCGal-Trp. HA-tagged Cln proteins were isolated from log-phase cultures, and kinase assays were performed. Cln proteins and Cln-associated Cdc28 protein were analyzed by immunoblotting. All protocols were as described in Materials and Methods. Values were obtained by standardizing H1 radioactivity to Cln-associated Cdc28 protein levels. Bar graphs show relative values, standardized to wild-type Cln2 values, and represent the averaged values of samples prepared in duplicate. For unknown reasons, the levels of Cln3-associated Cdc28 protein and Cln3-associated Cdc28-specific kinase activity were not reproducible between experiments and are therefore reported as not determined (N.D.) (see text). In this particular experiment, the Cdc28/Cln3 ratio was 0.224, and the kinase activity/Cdc28 activity ratio for Cln3 was 0.185. The Cdc28 protein and specific kinase activities for the cln2KAEA samples were too low to be accurately quantified and are also indicated as N.D.
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cyclin A (and presumably in Cln2), and so we consider it likely that these mutations specifically affect Cdc28 binding rather than altering overall folding of Cln2. Therefore, we expect that these mutant proteins are essentially quantitatively reduced for function rather than generally misfolded. Consistent with this interpretation, we note that the specific activity of kinase associated with K129A or E183A was similar to wild-type activity, suggesting that the reduced amount of Cdc28 that associated with the mutant Cln2 proteins was in the active conformation. Cln2, Cln3, and mutant Cln2 abundance. To evaluate the protein levels of Cln2, Cln3, and the Cln2 mutants when expressed from the CLN3 promoter (the plasmid constructs used in the functional assays described below), protein extracts from transformants of a wild-type strain containing these plasmids were immunoprecipitated and immunoblotted to determine the relative levels of Cln protein. Following the reasoning of Tyers et al. (44), we assume that signal intensity will likely reflect protein abundance since both proteins are tagged identically at their C termini (with the caveat that we must assume identical accessibility of the tag to antibody). We found that wild-type Cln2 was apparently about fivefold more abundant than Cln3 when both were expressed from the CLN3 promoter ( Fig. 2 and data not shown) . (The abundance of Cln2 protein when expressed from the CLN3 promoter was roughly equivalent to its abundance when expressed from the wild-type CLN2 promoter [data not shown].) A direct test of stability of Cln2 and Cln3 (by turning off transcription from the GAL1 promoter in strains containing GAL1::CLN2C or GAL1:: CLN3C in parallel) revealed short half-lives (about 10 min) in each case (data not shown). Hence, we do not know the molecular basis for this difference in abundance between Cln2 and Cln3. The K129A and E183A mutant Cln2 proteins were somewhat more abundant than wild-type Cln2.
In an attempt to equalize the protein levels of wild-type Cln2 and Cln3, we transferred the CLN3 gene from the low-copynumber vector (RS314) used in the analysis described above to the high-copy-number vector RS424 (5). The Cln3 protein levels in transformants containing this high-copy-number plasmid were roughly equivalent to those of wild-type Cln2 when expressed from the low-copy-number plasmid, about four-to fivefold higher than the levels of Cln3 in transformants containing the low-copy-number plasmid (Fig. 2) .
Functional assays for CLN2 and CLN3. The basic assay for CLN function is complementation of a cln1 cln2 cln3 mutant strain (39) . When expressed under the control of the CLN3 promoter, CLN2, CLN3, CLN2-E183A, and CLN2-K129A are positive in the cln1 cln2 cln3 rescue assay. CLN2-K129A is detectably weaker (Fig. 3A) and is also temperature sensitive (Fig. 4) . CLN2-K129A,E183A is essentially negative for rescue even at 30ЊC (Fig. 3A and 4) .
In addition to the complementation of a cln1 cln2 cln3 strain, the efficiency of CLN rescue can be assessed by the cell volume of rescued strains, since CLN overexpression drives bud emergence and reduces cell volume (6, 15, 32, 39) . When tested for cell volume, the apparent order of potency of the genes was CLN2 Ͼ CLN3 Ͼ CLN2-E183A Ͼ CLN2-K129A (Fig. 5) .
To further evaluate CLN2, CLN3, and the CLN2 mutants under the control of the CLN3 promoter, we made use of a series of mutant strains that functionally differentiate between CLN2 and CLN3. As summarized in Fig. 4 , mutant strains were transformed with the CLN2, CLN3, and CLN2 mutant plasmids and tested for viability with the plasmid-encoded CLN gene as the only functional CLN gene in the cell. As predicted from published work (see the introduction and reference 7 for fuller discussions), CLN3 is unable to rescue cln1 cln2 cln3 strains that are also deficient in the SWI4 or SWI6 genes encoding components of the transcription factor SCBbinding factor (SBF) (see reference 27 for a review), the CLB5-CLB6 pair of B-type cyclins (41), the PCL1-PCL2 pair of cyclin homologs (30, 36) , and the BUD2 gene (because cell polarization is defective) (4, 12) . In contrast, CLN2 under the control of the CLN3 promoter rescues all of these mutant backgrounds ( Fig. 4; see Fig. 3B for the example of the swi4 assay). This result formally proves that the coding sequence of CLN2 rather than its promoter is specifically responsible for its greater activity in these assays. (In contrast, cln1 cln2 rad27 strains [defective in S-phase completion {38, 47}] are much better rescued by CLN2 coding sequences under control of the CLN2 promoter compared to the CLN3 promoter [data not shown].)
In the absence of CLN1 and CLN2, overexpression of the Sic1 inhibitor of B-type cyclin-Cdc28 kinases (31, 40) is lethal (43a). This may reflect reduced ability of Cln3-Cdc28 compared to Cln1-or Cln2-Cdc28 to trigger Sic1 degradation (40) , although this has not been established as yet. We transformed a cln1 cln2 CLN3 GAL1::SIC1 strain with the various CLN genes under control of the CLN3 promoter. We found at least a 1,000-fold-lower plating efficiency for CLN3 compared to CLN2 (Fig. 4) .
The CLN2-K129A mutant was reduced in activity compared to the wild type in these assays (Fig. 4) , while the CLN2-E183A mutant displayed lesser but detectable defects. The CLN2-K129A,E183A mutant was negative in these assays. These results are consistent with a simple linear ordering of strength of these alleles: CLN2 Ͼ CLN2-E183A Ͼ CLN2-K129A Ͼ CLN2-K129A,E183A. CLN3 is at most slightly more active than the CLN2-K129A,E183A in these assays (Fig. 4) . VOL. 16, 1996 FUNCTIONAL SPECIFICITIES OF YEAST G 1 CYCLINS 6797
When we tested rescue of a cln1 cln2 cln3 bck2 strain, the results were quite different. The order of strength of the genes tested became CLN2 м CLN3 Ͼ CLN2-E183A ӷ CLN2-K129A м CLN2-K129A,E183A (Fig. 3C and 4) . Note that this order is similar to the order derived from cln1 cln2 cln3 rescue and cell volume assays (Fig. 3A, 4 , and 5). The CLN2-E183A mutant, which was nearly as active as CLN2 in most of the assays in which CLN3 was negative, was reproducibly reduced about 10-fold in plating efficiency in the cln1 cln2 cln3 bck2 background.
As mentioned, we detected about a fivefold reduction in Cln3 abundance compared to Cln2 when expressed from the CLN3 promoter (Fig. 2) . To see if reduced abundance of Cln3 could account for its deficit in many of these assays, we repeated these assays using transformants containing the highcopy-number CLN3 plasmid described above. Increasing CLN3 copy number significantly improved rescue of the cln1 cln2 cln3 swi4 and cln1 cln2 cln3 clb5 clb6 backgrounds, which were rescued with reasonable efficiency by the high-copy-number CLN3 gene at 30ЊC but not at 38ЊC. Increasing CLN3 copy number did not improve rescue of cln1 cln2 cln3 strains containing bud2, swi6, or pcl1 pcl2 mutations. The failure of CLN3 to rescue many of these genetic backgrounds thus cannot be attributed simply to low Cln3 protein levels compared to Cln2, since the high-copy-number CLN3 plasmid yielded Cln3 protein levels similar to those of Cln2 expressed from the lowcopy-number CLN2 plasmid (Fig. 2) . (As a caveat, it should be noted that Cln protein levels expressed from these plasmids [ Fig. 2 ] were evaluated in a CLN1 CLN2 CLN3 wild-type strain rather than in these mutant backgrounds. We cannot exclude an effect of the mutant background or of selection for function on Cln protein levels in these contexts; moderate plasmid copy -3P ), or pRS414. Except for the 2m CLN3 (high-copy-number) plasmid, all plasmids are episomal CEN (low copy number). For each transformed strain, 10-fold serial dilutions were prepared for two independently isolated transformants, and 5 l of each dilution was plated onto both a YEPGal (GAL1::CLN1 on) and YEPDex (GAL1::CLN1 off) plate. Plates were incubated at 30ЊC for 2 days.
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number variation also could play a role, even though these plasmids contain a CEN conferring reasonable stability of low copy number [2] .) Activation of Bck2-independent SCB-dependent transcription. Bck2 may encode a transcriptional activator of CLN1, CLN2, and other genes (14, 20) ; it contains a potent transcriptional activation domain (22a). One way to explain the strong differences in rescue for the different CLN genes with the bck2 assay compared to the other assays would be to suppose that this reflects Cln3-dependent, Bck2-independent transcriptional activation of a target gene(s) required for Start (14, 20) . As a test of this, we compared the abilities of CLN3, CLN2, CLN2-E183A, and CLN2-K129A expressed from the CLN3 promoter to activate transcription from an SCB reporter gene when these genes were the only functional CLN genes present in the cell. The SCB sequence is responsive to Swi4/Swi6 control (see reference 27 for a review), and both Cln3 and Bck2 may activate expression independently through this sequence Except for the 2m CLN3 (high-copy-number) plasmid, all plasmids are episomal CEN (low copy number). A representative experiment for the strains represented by bars 1, 3, and 9 is shown in Fig. 3 . The plating efficiencies indicated on each graph represent the averaged values (arithmetic mean) of two independent transformants. Note that the bud2 and pcl1 pcl2 assays were done at 38ЊC to tighten the restriction of rescue by CLN3 (reference 4 and data not shown). To control for this, rescue of a cln1 cln2 cln3 BUD2 PCL1 PCL2 strain (1254-14D) at 38ЊC was also determined (bars 2).
FIG. 5. Cell volume assay for CLN gene function. Cells of the cln1 cln2 cln3
(1254-14D) strain containing the GAL1::CLN1 gene, which is essential for viability, were transformed with plasmid T411 (CLN2-3P), KL004 (cln2 E183A-3P), KL003 (cln2 K129A-3P), or KL001 (CLN3-3P). All plasmids are episomal CEN (low copy number) and carry the TRP1 gene. Cell volume analysis was carried out as described in Materials and Methods. Data points for each of two transformants are shown together on each graph. The average modal volume for each strain was calculated, and relative sizes standardized to the CLN2 transformants are indicated.
VOL. 16, 1996 FUNCTIONAL SPECIFICITIES OF YEAST G 1 CYCLINS 6799 (14, 20, 43) . In a BCK2 background, a moderate level of CLNindependent expression was observed as expected (reference 20 and data not shown), making it difficult to accurately determine the effects of the CLN genes. Therefore, we made cln1 cln2 cln3 bck2 GAL1::CLN3 strains carrying an SCB-lacZ reporter and also containing vector, CLN2, CLN3, CLN2-K129A, or CLN2-E183A (all under control of the CLN3 promoter) and shifted these strains from galactose to glucose medium to turn off the GAL1::CLN3 gene. After 24 h, we analyzed ␤-galactosidase activity. CLN3 was more active than CLN2, CLN2-E183A showed a further reduction in efficiency, and CLN2-K129A was little more effective than the vector control at this induction (Fig. 6 ). An important caveat to the interpretation of this assay, however, is the possibility that the greater activity of CLN3 than of CLN2 is at least in part due to CLN2's greater ability to promote transcriptional inactivation of SCB-dependent gene expression (15, 43) . Dosage studies of CLN2 and CLN3 support a primary role for Cln3 in activating CLN2 transcription. Stuart and Wittenberg (43) and Dirick et al. (15) presented evidence that the potential positive feedback loop for activating CLN1 and CLN2 transcription (10, 16) was likely not to be of much or any significance in dictating timing of CLN1 and CLN2 transcription compared to Cln3 activation of transcription of these genes. These studies relied on fairly drastic manipulations (medium shifts to inactivate conditional CLN gene overexpression and elutriation of large volumes of chilled culture followed by reinoculation into warm medium of very small G 1 -phase cells) and on comparison of wild-type with cln1 cln2 strains, which are known to have many defects in cell cycle initiation and progression (see the introduction). We wanted to test this idea in a less manipulative way. We reasoned that if positive feedback were important in the onset of CLN1 and CLN2 transcription, then doubling the CLN2 gene dosage should dramatically affect CLN2 transcription by providing twice the amount of "substrate" for positive feedback to feed back upon. We therefore compared the relationship of cell size, bud emergence, and CLN2 and histone H2A transcript levels in diploid strains containing one or two copies of the CLN2 gene (and no functional CLN1 gene and only one CLN3 gene, to increase sensitivity to effects of CLN2). This analysis was performed simply by chilling and size fractionating log-phase cultures, and so manipulation was minimal; also, the strains compared differed only in CLN2 or CLN3 gene dosage, rather than in the presence or complete absence of CLN genes as in the previous studies (15, 43) . We found (Fig. 7A ) that in strong contrast to the expectation of positive feedback, doubling the CLN2 gene dosage somewhat less than doubled the level of CLN2 transcription and had little or no effect on the cell volume at which CLN2 transcription initiated. Also, we found that cln1 CLN2/cln2::LEU2 CLN3/cln3-del diploids executed bud emergence at a cell volume identical to that of isogenic CLN2/CLN2 strains, suggesting that Cln2 (once activated) is in excess for driving bud emergence. In contrast, increasing the number of CLN3 genes in a diploid of genotype cln1-del CLN2/cln2::LEU2 from one to four significantly decreased the cell volume of budding, peak CLN2 transcription, and peak histone H2A transcription in parallel (Fig. 7B) . (An increase in CLN3 gene dosage from one to two had a somewhat lesser effect [data not shown].) In a similar analysis, we found that cln1 cln2 strains were significantly delayed in bud emergence even after activating a high level of reporter cln2 transcription, consistent with previous reports (15, 43) (data not shown). These results clearly confirm previous conclusions (15, 43, 44) that Cln3 is the primary initiator of CLN2 transcription, that CLN2 has no obvious role in driving its own transcription, and that Cln2 (and not Cln3) is highly active in driving bud emergence.
These results fit well with the genetic studies reported above showing that Cln3 may be specialized for transcriptional activation.
DISCUSSION
Is Cln3-Cdc28 a "weak" kinase? Tyers et al. (44) observed very low recovery of both Cln3 protein and Cln3-associated kinase activity compared to Cln1 and Cln2. Their results did not address whether the low Cln3-associated kinase activity was simply a reflection of the relatively low amount of Cln3 protein or resulted from additional defects in Cln3-associated specific activity. We have confirmed the observation that Cln3 is significantly less abundant than Cln2 (Fig. 2 and data not shown). After standardizing for amount of Cln protein, we could still detect a significant defect in Cln3-associated kinase activity relative to Cln2 (Fig. 1) . It seems likely that Cln3-associated kinase is indeed much less active than Cln2-associated kinase under these conditions and using histone H1 as the substrate. However, the implication from the results reported here, that Cln3-Cdc28 may be specialized for a narrower range of substrates than Cln2-Cdc28, means that a fair comparison of the two enzyme activities must await identification of appropriate physiological substrates. (A differential adverse effect of the epitope tag on Cln3-associated and Cln2-associated kinases also cannot be ruled out at present.)
Is Cln3 specialized for transcriptional activation? Recent experiments (15, 43, 44) have suggested that Cln3 is the primary in vivo activator of transcription of CLN1, CLN2, PCL1, PCL2, CLB5, and CLB6; while Cln1 and Cln2 can activate transcription of these genes, it has been suggested that they do not contribute significantly to this activation under physiological conditions. These conclusions were confirmed in a different analysis (Fig. 7) . However, since CLN3 transcription is less tightly regulated and initiated earlier than that of CLN1 and CLN2 (4a, 34, 44) , the apparently specialized role of Cln3 in activating transcription could simply reflect its time of expression rather than any higher activity. Indeed, Stuart and Wittenberg (43) suggested that when placed under control of the CLN3 promoter, Cln2 was at least as good at activating transcription from the CLN2 promoter as was Cln3. Our results, obtained by using a simple reporter construct (SCB-lacZ) rather than the more complex CLN2 promoter, show that Cln3 is probably at least as active as Cln2 at activating SCB-dependent transcription (given the caveat discussed above concerning the possibility that Cln2 could be more active than Cln3 at inducing shutoff of SCB-dependent transcription; this issue is thoroughly discussed in reference 43). This occurs with both CLN2 and CLN3 coding sequences under control of the CLN3 promoter, conditions under which Cln2 accumulates to about fivefold-higher levels than does Cln3 (Fig. 2 and data not  shown) . The CLN2-E183A and CLN2-K129A mutants have greatly reduced ability to induce SCB-dependent transcription, despite their retaining significant biological activity (much higher than CLN3) in many functional assays. These proteins also accumulate to higher levels than either Cln2 or Cln3 (Fig.  2) , and so low protein levels do not account for their defect in transcriptional activation. It is striking that these mutants are most defective in the transcriptional activation assay, which is the function most clearly comparable between wild-type CLN2 and CLN3. This result is inconsistent with the idea that CLN3 is equivalent to a weak version of CLN2; rather, it is likely specialized to activate transcription even when expressed at low levels. The effects of alteration of CLN2 and CLN3 gene dosage on timing of CLN2 transcription described above (Fig.  7 ) also fit with this conclusion. It remains unclear how Cln-Cdc28 activity results in activation of expression of Swi4-Swi6-and Mbp1-Swi6-dependent genes (27) . Shutoff of Swi4-regulated genes correlates with activation of Clb-Cdc28 complexes and coincident displacement of Swi4 from its in vivo binding sites (28) ; however, Swi4 binding is regained upon exit from mitosis, before Swi4-dependent and Cln-dependent gene expression occurs. Mbp1 DNA binding through the cell cycle has not been characterized. Mbp1 becomes essential only in the absence of Swi4 (26) . Unlike SWI4, MBP1 can be disrupted with no effect on viability of cln1 cln2 cln3 strains transformed with the CLN2, CLN3, or mutant CLN2 constructs used in these experiments (data not shown).
Cyclin specificity. The genetic data discussed above showed that Cln2 (even when crippled) is more active than Cln3 in some assays, but Cln3 is as active as Cln2 and more active than crippled Cln2 in others. In formal terms, CLN3 cannot be fit in an allelic series with these mutant CLN2 genes, meaning that it probably differs qualitatively rather than (only) quantitatively. These results are most easily interpreted by assuming that Cln3 has a different in vivo substrate specificity than Cln2.
The logic of this interpretation requires assuming the crippled Cln2 proteins to be quantitatively reduced in function, rather than themselves having altered substrate specificity compared to wild-type Cln2. While we cannot prove this assumption, the observation that the mutants show strong reductions in Cdc28 binding, but little or no defect in specific activity FIG. 7 . CLN gene dosage and cell cycle initiation. Diploid strains were constructed with various CLN2 and CLN3 gene dosages. In these diploid strains, CLN1 was homozygously deleted to enhance detection of effects of CLN2 and CLN3 dosage. Strains were grown to log phase in YEPD, and cultures were quick-chilled on ice, collected by centrifugation, sonicated, and fractionated by centrifugal elutriation at 0 to 4ЊC as described in Materials and Methods (spun at 3,000 rpm in panel A and at 2,800 rpm in panel B). Fractions were analyzed for proportion of unbudded cells and for CLN2, H2A, and TCM1 RNA content by RNA hybridization analysis followed by PhosphorImager quantitation. CLN2 and histone H2A transcript levels were normalized to transcript levels for TCM1 to standardize loading as described previously (35 VOL. 16, 1996 FUNCTIONAL SPECIFICITIES OF YEAST G 1 CYCLINS 6801 of the kinase normalized using bound Cdc28, is consistent with the idea that the mutants are quantitatively reduced in function strictly due to a Cdc28 binding defect. However, the CLN2-K129A mutant has significantly greater in vivo defects than the CLN2-E183A mutant, and we cannot account for these differences on the basis of measurement of in vitro associated kinase activity. This inconsistency weakens the logic of the interpretation. However, a stronger effect of the K129A mutant than of the E183A mutant can be rationalized on the basis of the cyclin A-Cdk2 structure, since the equivalent lysine residue K266 makes two hydrogen bonds to the PSTAIRE helix, while the equivalent glutamic acid residue E295 makes only one (24) . The in vitro measurements reflect only the amount of Cdc28 that remains bound to Cln2 following immunoprecipitation and multiple washes and therefore may not exactly reflect the amount bound in vivo, especially for mutant cyclins that bind more weakly. The crystal structure of cyclin A-Cdk2 shows that cyclin is bound to approximately the opposite side of Cdk2 from the presumed substrate binding region. This fact could interfere with speculation as to the mechanism by which cyclins could contribute to substrate selectivity. Possible mechanisms could include (i) interaction of cyclin with substrates at regions distant from the site of phosphorylation (possible example from a mammalian system: cyclin D prefers Rb as a target and interacts with Rb in the pocket region [17, 25] ), (ii) altered subcellular localization of different cyclins controlling substrate access (as suggested for cyclin B1 and cyclin B2 [23] ), and (iii) altered conformation of the substrate binding cleft due to allosteric effects of different modes of binding of cyclins to the kinase. Several cases of substrate preference or specificity for mammalian cyclins, with the cyclins complexed to the same cyclin-dependent kinase, have been reported (37, 48) . Substrate specificity has been inferred from strong biological specificity of cyclin action in situations in yeast where substrates have not yet been identified (1, 19, 29, 34, 41) .
Cln2 and Cln3 are "functionally redundant" proteins that probably have quite different mechanisms of action. Our interpretation of the roles of Cln1 and Cln2 compared to Cln3 in wild-type and mutant cells is outlined in Fig. 8 . In wild-type cells (Fig. 8A ), Cln1 and Cln2 directly activate pathways leading to the processes of bud emergence, morphogenesis, and DNA replication. Cln3, perhaps specialized for transcriptional activation, acts through the Swi4 and Swi6 (and possibly Mbp1) transcription factors to activate the transcription of CLN1, CLN2, PCL1, PCL2, CLB5, and CLB6 (27) . Bck2 is also involved in the transcription of these genes, probably in a Clnindependent manner (14, 20) . Bud2 and Cla4 are factors facilitating budding and cell morphogenesis (4, 11, 12) . In cells containing CLN3 as the only functional CLN gene (Fig. 8B) , the pathway leading to bud emergence, morphogenesis, and DNA replication is dependent on the activities of the Swi4 and Swi6 transcription factors, the Clb5-Clb6 and Pcl1-Pcl2 cyclin pairs, and the Bud2 and Cla4 budding factors (4, 11, 12, 30, 33, 41) . Bck2 plays a nonessential role in the Cln3-activated pathway. In cln1 CLN2-3P cln3 cells (Fig. 8C) , the transcription of CLN2 from the CLN3 promoter is not dependent on the activities of Bck2, Swi4, or Swi6. The Cln2 pathway leading to bud emergence, morphogenesis, and DNA replication is not dependent on the activities of the Clb5-Clb6 or Pcl1-Pcl2 cyclin pair or the Bud2 and Cla4 budding factors. Thus, once the requirement for Cln3 to efficiently activate CLN2 transcription is eliminated, it becomes clear that Cln2 directly activates many events that Cln3 can activate only via a complex pathway.
The probable biological specialization of Cln3 for transcriptional activation, as indicated by physiological and genetic studies (see reference 7 for a review), is shown here to be accompanied by intrinsic functional specialization of the kinase, possibly due to selective targeting. Cln2-Cdc28, in contrast, may perform multiple roles in driving the Start transition (4, 7, 11, 12) . How many independent specificities or targeting functions are required to account for the apparently diverse activities of Cln2 revealed by these genetic studies remains to be determined.
